Factores clínico-epidemiológicos asociados a litiasis residual en pacientes sometidos a litotricia láser by Saul E. Velázquez-Guerrero, Luis A. Gastélum-Félix, Julio A. Ruiz-Torres, Uziel F. Rodríguez-Muñoz, Juan A. Lugo-Machado

“…Conclusiones: El tamaño del lito y el historial de cirugía renal previa son factores asociados con la presencia de litiasis residual después de una URSFLL en pacientes con diagnóstico de litiasis renal.…”
Get full text

Epidemiological aspects of nephrolithiasis and chronic diseases of the cardiovascular system combination by R. V. Royuk, S. K. Yarovoy, N. A. Guseva, Sh. L. Voskanyan, V. V. Royuk, D. B. Rodin

“…In a period between 2009 and 2018, was made a retrospective analysis of medical histories of 2311 patients with urolithiasis, which were treated in in the urology departments of the branch No. 1 of the MCHG named after N.N. …”
Get full text

Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phas... by Jorge E. Cortes, Gail J. Roboz, Maria R. Baer, Brian A. Jonas, Gary J. Schiller, Karen Yee, P. Brent Ferrell, Jay Yang, Eunice S. Wang, William G. Blum, Alice Mims, Hua Tian, Aaron Sheppard, Stéphane de Botton, Pau Montesinos, Antonio Curti, Justin M. Watts, the Olutasidenib Combination Therapy Study Group

“…Conclusions Olutasidenib plus azacitidine induced high response rates and durable remissions with a tolerable side effect profile in patients with R/R AML with diverse treatment histories. The results represent another therapeutic option for patients with mIDH1 AML who may benefit from a targeted therapy. …”
Get full text